{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:55Z","timestamp":1789785355245,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:00:00Z","timestamp":1673136000000},"content-version":"vor","delay-in-days":237,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose\u2013responses among patients. The aim of this study was to provide clinical guidance on dosing and titration of the novel long-acting GH derivative somapacitan based on analyses of somapacitan dose\u2013insulin-like growth factor I (IGF-I) responses in AGHD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Analyses of dosing information, 4364 somapacitan concentration samples and 4880 IGF-I samples from 330 AGHD patients treated with somapacitan in three phase 3 trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pharmacokinetic\/pharmacodynamic modelling was used to evaluate starting dose groups by age and oral oestrogen therapy, characterise the dose\u2013IGF-I response in the overall AGHD population and patient subgroups, predict the IGF-I response to dose changes and simulate missed dosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analyses supported the clinical recommendations of higher starting doses for younger patients and women on oral oestrogen replacement therapy. For patients switching from daily GH treatment, the mean maintenance dose ratio between somapacitan (mg\/week) and somatropin (mg\/day) was predicted to be 8.2 (observed interquartile range of 6.7\u20139.1). Simulations of IGF-I SDS profiles confirmed the appropriate time for IGF-I sampling to be 3\u20134 days after somapacitan dosing and supported somapacitan administration with up to 3 days delay in case of missed dosing. Subgroup analyses characterised the dose\u2013exposure\u2013IGF-I response in patient subgroups and indicated that dose requirements are mainly influenced by sex and oral oestrogen treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study extends the knowledge of the somapacitan dose\u2013IGF-I response and provides information on clinical dosing of once-weekly somapacitan in patients with AGHD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1530\/eje-21-1167","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T10:06:01Z","timestamp":1651831561000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":13,"title":["Dose\u2013exposure\u2013IGF-I response of once-weekly somapacitan in adults with GH deficiency"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-9333","authenticated-orcid":false,"given":"Rasmus Juul","family":"Kildemoes","sequence":"first","affiliation":[{"name":"Global Development, Novo Nordisk A\/S , Bagsvaerd, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hollensen","sequence":"additional","affiliation":[{"name":"Global Development, Novo Nordisk A\/S , Bagsvaerd, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M K","family":"Biller","sequence":"additional","affiliation":[{"name":"Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-8440","authenticated-orcid":false,"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[{"name":"Institute of Medicine, Sahlgrenska Academy, University of G\u00f6teborg , G\u00f6teborg, Sweden"},{"name":"Department of Endocrinology, Sahlgrenska University Hospital , G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Nara Medical University , Kashihara, Japan"},{"name":"Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine , Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H\u00f8jby","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Clinical Drug Development, Novo Nordisk A\/S , S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2023010809165515900_bib1","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"2023010809165515900_bib2","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-18-0306","article-title":"Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"J\u00f8rgensen","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"2023010809165515900_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11102-007-0027-9","article-title":"IGF-I measurements in the monitoring of GH therapy","volume":"10","author":"Higham","year":"2007","journal-title":"Pituitary"},{"key":"2023010809165515900_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11154-020-09605-1","article-title":"Individual sensitivity to growth hormone replacement in adults","volume":"22","author":"Boguszewski","year":"2021","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"2023010809165515900_bib5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocrine Practice"},{"key":"2023010809165515900_bib7","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1530\/EC-18-0047","article-title":"Growth Hormone Research Society perspective on biomarkers of GH action in children and adults","volume":"7","author":"Johannsson","year":"2018","journal-title":"Endocrine Connections"},{"key":"2023010809165515900_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocrine Practice"},{"key":"2023010809165515900_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13030","article-title":"Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood?","volume":"84","author":"Auer","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"2023010809165515900_bib10","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"2023010809165515900_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17446651.2019.1689119","article-title":"Adult growth hormone deficiency: clinical advances and approaches to improve adherence","volume":"14","author":"Yuen","year":"2019","journal-title":"Expert Review of Endocrinology and Metabolism"},{"key":"2023010809165515900_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ghir.2017.05.006","article-title":"Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: a reversible non-covalent albumin-binding growth hormone","volume":"35","author":"Thygesen","year":"2017","journal-title":"Growth Hormone and IGF Research"},{"key":"2023010809165515900_bib13","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"2023010809165515900_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cen.14273","article-title":"Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone","volume":"93","author":"Otsuka","year":"2020","journal-title":"Clinical Endocrinology"},{"key":"2023010809165515900_bib16","volume-title":"Guideline for Good Cinical Practice E6","author":"ICH Harmonised Tripartite Guideline","year":"2016"},{"key":"2023010809165515900_bib17"},{"key":"2023010809165515900_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in Association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","journal-title":"European Journal of Endocrinology"},{"key":"2023010809165515900_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/clinem\/dgaa775","article-title":"Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan","volume":"106","author":"Juul Kildemoes","year":"2021","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40262-018-0662-5","article-title":"Pharmacokinetics and pharmacodynamics of once-weekly somapacitan in children and adults: supporting dosing rationales with a model-based analysis of three phase I trials","volume":"58","author":"Juul","year":"2019","journal-title":"Clinical Pharmacokinetics"},{"key":"2023010809165515900_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4088\/JCP.v61n1207","article-title":"Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder","volume":"61","author":"Claxton","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"2023010809165515900_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CEOR.S23158","article-title":"The role of Galenic innovation in improving treatment compliance and persistence: three case studies","volume":"3","author":"Zoellner","year":"2011","journal-title":"ClinicoEconomics and Outcomes Research"},{"key":"2023010809165515900_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","article-title":"Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA","volume":"10","author":"Kishimoto","year":"2015","journal-title":"Archives of Osteoporosis"},{"key":"2023010809165515900_bib25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.20945\/2359-3997000000189","article-title":"Personalized approach to growth hormone replacement in adults","volume":"63","author":"van Bunderen","year":"2019","journal-title":"Archives of Endocrinology and Metabolism"},{"key":"2023010809165515900_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/er.2003-0035","article-title":"Estrogen regulation of growth hormone action","volume":"25","author":"Leung","year":"2004","journal-title":"Endocrine Reviews"},{"key":"2023010809165515900_bib27","first-page":"E1191","article-title":"Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women","volume":"281","author":"Wolthers","year":"2001","journal-title":"American Journal of Physiology: Endocrinology and Metabolism"},{"key":"2023010809165515900_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem-72-2-374","article-title":"Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women","volume":"72","author":"Weissberger","year":"1991","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib29","first-page":"3956","article-title":"Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults","volume":"84","author":"Cook","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/mgme.1998.2685","article-title":"Regulation of growth hormone receptor gene expression","volume":"63","author":"Schwartzbauer","year":"1998","journal-title":"Molecular Genetics and Metabolism"},{"key":"2023010809165515900_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2265.1995.tb01908.x","article-title":"Which adults develop side-effects of growth hormone replacement?","volume":"43","author":"Holmes","year":"1995","journal-title":"Clinical Endocrinology"},{"key":"2023010809165515900_bib32","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib33","first-page":"34","article-title":"Growth hormone bioavailability, insulin-like growth factor-I and IGF-binding-protein-3 release in Japanese and Caucasian subjects","volume":"7","author":"Rasmussen","year":"2015","journal-title":"Journal of Bioequivalence and Bioavailability"},{"key":"2023010809165515900_bib34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1210\/jc.2004-0501","article-title":"Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity","volume":"90","author":"Gleeson","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000090121","article-title":"Individual igf-I responsiveness to a fixed regimen of low-dose growth hormone replacement is increased with less variability in obese compared to non-obese adults with severe growth hormone deficiency","volume":"65","author":"Yuen","year":"2006","journal-title":"Hormone Research"},{"key":"2023010809165515900_bib36","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib37","first-page":"1519","article-title":"Serum growth hormone-binding protein in obesity: effect of a short-term, very low calorie diet and diet-induced weight loss","volume":"81","author":"Rasmussen","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib38","first-page":"123","article-title":"Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults","volume":"82","author":"Fisker","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809165515900_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ghir.2005.11.001","article-title":"Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects","volume":"16","author":"Fisker","year":"2006","journal-title":"Growth Hormone and IGF Research"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/1\/EJE-21-1167.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/1\/27\/48515884\/eje-21-1167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/1\/27\/48515884\/eje-21-1167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:17:35Z","timestamp":1676391455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/1\/27\/6972088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-21-1167","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,5,16]]}}}